Human Papillomavirus Vaccine Market Size (2024 - 2029)

The human papillomavirus (HPV) vaccine market is anticipated to experience growth over the forecast period, driven by increasing demand due to the prevalence of HPV-related diseases such as cervical cancer. The market's expansion is supported by government and private initiatives for early screening and vaccination, as well as the approval of new vaccines. Despite the initial impact of the COVID-19 pandemic, which temporarily reduced demand, the market has rebounded as conditions improved. However, stringent regulations may pose challenges to market growth.

Market Size of Human Papillomavirus Vaccine Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Human Papillomavirus Vaccine Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 7.50 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Human Papillomavirus Vaccine Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Human Papillomavirus Vaccine Market Analysis

The human papillomavirus (HPV) vaccine market is expected to register a CAGR of nearly 7.5% during the forecast period.

As the pandemic hit, the screening and diagnosis of non-emergency diseases were postponed worldwide, which has impacted the studied market. As per a research study published in March 2021 in PubMed, 74% of the total respondent laboratories globally experienced a supply shortage for HPV tests for cervical cancer screening. Therefore, there was a reduction in cervical cancer and other related cancer screening, ultimately reducing the demand for the HPV vaccine during the pandemic. Furthermore, a research study published in January 2023 in Vaccines indicated that a 75% reduction in HPV vaccination coverage was observed in the United States during the initial phase of the pandemic as compared to the previous year. Hence, owing to the factors mentioned above, the COVID-19 pandemic significantly impacted the market studied. However, with the COVID-19 cases in control, the market regained its pre-pandemic nature in terms of demand for HPV vaccines. Furthermore, due to the increasing initiatives by government & private organizations for early screening & vaccination and approval of new HPV vaccines, the market is believed to witness significant growth over the forecast period.

The rising prevalence of HPV-related diseases such as cervical cancer, anal cancer, and genital warts is expected to boost the demand for HPV vaccines significantly. For instance, as per the India, HPV and Related Cancers, 2023 report, cervical cancer ranks as the 2nd most frequent cancer among women in India and the 2nd most frequent cancer among women between 15 and 44. As per the same source, 123,907 women are diagnosed with cervical cancer in India each year. Therefore, the high burden of cervical cancer is expected to boost the demand for HPV vaccine during the forecast period.

The initiatives by the government to fund the HPV vaccines and rising screening and immunization programs are expected to boost the market growth. For instance, according to an article published in January 2023 in Vaccines Journal, the HPV vaccine is fully funded for children aged 11-14 years old and for 15-26-year-old females in Switzerland. Also, in March 2022, in Greece, a gender-neutral HPV vaccination program was launched.

Furthermore, in January 2021, the United States Department of Health and Human Services launched the "HPV VAX NOW" campaign to increase HPV vaccination rates among young adults aged 18-26 years. Also, in November 2021, Saudi Arabia launched a human papillomavirus infection program for young girls aged 9-13 years to prevent them from developing cervical cancer. This is expected to increase the development of HPV-cervical cancer vaccines hence bolstering the market growth.

Therefore, the factors such as the high burden of cervical cancer and rising screening and immunization programs, and launches of vaccines, the studied market is expected to witness growth during the forecast period. However, stringent regulation is likely to hinder market growth over the forecast period.

Human Papillomavirus Vaccine Industry Segmentation

As per the scope of this report, human papillomavirus vaccines are vaccines that are utilized to prevent HPV infection. HPV is a group of more than 100 viruses, of which 13 can cause cancer, and nearly all cases of cervical cancer are attributed to HPV. The human papillomavirus vaccine market is segmented by type (bivalent, quadrivalent, nonavalent), indication (cervical cancer, anal cancer, penile cancer, oropharyngeal cancer, genital warts, and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.

By Type
Bivalent
Quadrivalent
Nonavalent
By Indication
Cervical Cancer
Anal Cancer
Penile Cancer
Oropharyngeal Cancer
Genital Warts
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Human Papillomavirus Vaccine Market Size Summary

The human papillomavirus (HPV) vaccine market is poised for significant growth, driven by increasing awareness and initiatives aimed at combating HPV-related diseases such as cervical cancer, anal cancer, and genital warts. The market experienced a temporary setback during the COVID-19 pandemic due to disruptions in screening and vaccination efforts, but has since rebounded as demand returned to pre-pandemic levels. Government and private sector initiatives, including funding and new vaccine approvals, are expected to further propel market expansion. The high prevalence of cervical cancer, particularly in regions like India, underscores the urgent need for HPV vaccination, thereby boosting market demand.

North America is anticipated to maintain a substantial share of the HPV vaccine market, supported by robust healthcare infrastructure and a high incidence of HPV-related cancers. The region benefits from strategic initiatives by market players, such as vaccine launches and approvals, which are expected to drive growth. The competitive landscape is characterized by a few major players, including Merck & Co., Inc., GSK plc, and Serum Institute of India Pvt. Ltd., who hold significant market shares. Collaborative efforts, such as partnerships for cancer awareness and screening programs, further enhance market prospects. Overall, the market is set to experience healthy growth, albeit with potential challenges from stringent regulations.

Explore More

Human Papillomavirus Vaccine Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Approval of New HPV Vaccines

      2. 1.2.2 Increasing Initiatives by Government & Private Organizations for Early Screening & Vaccination

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulation

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Type

      1. 2.1.1 Bivalent

      2. 2.1.2 Quadrivalent

      3. 2.1.3 Nonavalent

    2. 2.2 By Indication

      1. 2.2.1 Cervical Cancer

      2. 2.2.2 Anal Cancer

      3. 2.2.3 Penile Cancer

      4. 2.2.4 Oropharyngeal Cancer

      5. 2.2.5 Genital Warts

      6. 2.2.6 Others

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Human Papillomavirus Vaccine Market Size FAQs

The Global Human Papillomavirus Vaccine Market is projected to register a CAGR of 7.5% during the forecast period (2024-2029)

Serum Institute of India Pvt. Ltd., Wantai BioPharm, INOVIO Pharmaceuticals, Merck & Co., Inc. and GSK plc. are the major companies operating in the Global Human Papillomavirus Vaccine Market.

Human Papillomavirus Vaccines Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)